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Clozapine-induced hypersalivation is a stigmatizing and debilitating side effect of clozapine treatment 
that may threaten adherence to treatment [Taylor et al. 2009]. Hyoscine hydrobromide is the most 
popular treatment for hypersalivation, but has a poor evidence base [Syed et al. 2008]. 
 
During autumn 2013, a shortage of hyoscine tablets in the UK (due to production problems) required 
patients who had been prescribed hyoscine to change to a replacement medication. This provided an 
opportunity to assess the subjective relative efficacy of hyoscine hydrobromide compared with 
alternative medications in the treatment of clozapine-induced hypersalivation. We undertook a 
service evaluation and surveyed patients prescribed clozapine at Ashworth Hospital (Mersey Care NHS 
Trust) who had been prescribed hyoscine hydrobromide for hypersalivation. Participants were 
prescribed alternative medication for clozapine-induced hypersalivation by September 2013 and we 
conducted our survey in November 2013. 
 
Of the 42 consenting participants, 15 were prescribed pirenzepine, 13 were prescribed atropine, and 
6 were prescribed a small number other replacement medications (procyclidine, orphenedrine, 
hyoscine patches) which, owing to small sample sizes, were excluded from our analysis. Eight patients 
previously prescribed hyoscine were prescribed no replacement medication. In each case, we asked 
patients to rate on a 7 point scale (1 = much worse, 4 = no change, 7 = much better) their current 
experience of nocturnal salivation, daytime salivation and a number of other side effects (vision 
problems, dizziness) compared with when previously prescribed hyoscine. 
 
Table 1. Mean rated changes in side effects according to replacement medication groups. 
 
Group n Nocturnal 
salivation 
Daytime 
salivation 
Vision 
problems 
Dizziness 
Pirenzepine 15 6.3 (1.0) 5.9 (1.1) 4.4 (0.9) 4.0 (1.0) 
Atropine 13 6.6 (0.5) 6.4 (0.6) 4.2 (0.4) 4.0 (0.0) 
No replacement 8 4.0 (0.0) 4.0 (0.0) 4.0 (0.0) 4.0 (0.0) 
Standard deviation in parentheses. 
 
Mean ratings of subjective relative efficacy in comparison with hyoscine for each of the three 
medication groups (pirenzepine, atropine, no replacement) are shown in Table 1. Subjective ratings 
showed that nocturnal salivation improved for both the pirenzepine group and the atropine group, 
but all patients in the no replacement group reported unchanged scores in night salivation. A one way 
analysis of variance (ANOVA) showed this to be statistically significant [F(2,35) = 34.36, p < 0.001], 
with post hoc Tukey tests suggesting that ratings in the pirenzepine and atropine groups were both 
higher than in the no replacement group. Similarly, ANOVA confirmed that changes in daytime 
salivation for the pirenzepine group and the atropine group were significantly different to the no 
replacement group which again reported no change [F(2,35) = 23.4, p < 0.001]. This is unlikely to be a 
general reporting bias in the pirenzepine and atropine groups because the three groups did not differ 
in their ratings of changes in vision problems [F(2,35) = 0.99, p = 0.38] and dizziness [F(2,35) = 0.0, p = 
1.0].  
 
Participants who ceased taking hyoscine and with no replacement medication reported no change in 
hypersalivation. By comparison, participants who replaced hyoscine with pirenzepine or atropine 
consistently reported an improvement in salivation (day and night). It should be noted that our service 
evaluation survey did not implement any randomization to groups and that the data are in the form 
of retrospective report, both of which limit the interpretation of the outcome. Nevertheless, whilst 
hyoscine hydrobromide is the treatment of choice for clozapine-induced hypersalivation, a Cochrane 
Review has indicated that the evidence base is weak [Syed et al. 2008]. There is a broad range of 
treatment alternatives but these appear equally unsupported in the literature. Thus, clinicians are 
forced to make pragmatic prescribing judgements in the absence of reliable evidence. Our small scale 
survey suggests that hyoscine may not be an effective treatment for hypersalivation and there is a 
clear need for more convincing evidence of the efficacy of treatments to confidently inform clinical 
practice. Indeed, a feasibility study funded by the UK National Institute for Health Research (NIHR) to 
investigate glycopyrrolate and hyoscine in the treatment of clozapine-induced hypersalivation is 
currently being conducted by our clinical team. 
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